Resistance in the anti-angiogenic era: nay-saying or a word of caution?

被引：28

作者：

Sweeney, CJ

Miller, KD

Sledge, GW

机构：

[1] Indiana Univ, Indianapolis, IN 46202 USA

[2] Indiana Univ, Div Hematol & Oncol, Indianapolis, IN 46202 USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2003年 / 9卷 / 01期

关键词：

D O I：

10.1016/S1471-4914(02)00007-2

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The hope that anti-angiogenic therapy might be the panacea for cancer has not yet been realized. There are many possible reasons for this, including endothelial and tumor cell heterogeneity, the presence of survival factors within the tumor micro-environment, the problem of defining the best dose and schedule for anti-angiogenic therapies, and angiogenesis-independent regrowth of tumors. Once these problems are understood, we can begin to evaluate approaches to thwarting them. These could include combining anti-angiogenic therapies with chemotherapy, with other anti-angiogenic agents or with other biological therapies. Another approach would be to employ a particular agent or combination of agents that target processes crucial to the survival of a particular cancer.

引用

页码：24 / 29

页数：6

共 54 条

[1] Human hormone-refractory prostate cancers can harbor mutations in the 02-dependent degradation domain of hypoxia inducible factor-1α (HIF-1α) [J].